

Evaluation of Ankylosing Spondylitis Quality of Life (EASi-QoL): Reliability and Validity of a New Patient-reported Outcome Measure

KIRSTIE L. HAYWOOD, ANDREW M. GARRATT, KELVIN P. JORDAN, EMMA L. HEALEY,
and JONATHAN C. PACKHAM

ABSTRACT. Objective. There is currently no universally accepted measure of quality of life in ankylosing spondylitis (AS). Our objective was to develop and evaluate a patient-reported outcome measure of quality of life in AS, EASi-QoL.

Methods. We used patient interviews, a literature review, and completion of an individualized measure of AS quality of life during clinic-based and pilot surveys to derive questionnaire content. Classical and modern psychometrics were then used to evaluate the questionnaire using data from a large UK-based postal survey of 1000 patients with AS.

Results. Data analysis from the interviews and clinic-based and postal surveys produced a 57-item self-completed questionnaire. Fifteen items were removed as a result of patient interviews and the pilot survey. In total, 612 (64.0%) patients responded to the main postal survey. After assessment of data quality, confirmatory factor analysis, and Rasch analysis, 20 items were found to contribute to 4 domains of AS-related quality of life: physical function, disease activity, emotional well-being, and social participation. Item-total correlations ranged from 0.66 to 0.84. Cronbach's alpha and test-retest reliability estimates were 0.88–0.92 and 0.88–0.93, respectively. Confirmed hypothesized correlations with the AS Quality of Life questionnaire, the Bath AS Disease Activity Index, Bath AS Functional Index, SF-36, EQ-5D, and the Hospital Anxiety and Depression Scale were evidence for the construct validity of the EASi-QoL.

Conclusion. The EASi-QoL has good evidence of data quality, internal reliability, test-retest reliability, and content and construct validity, and should be considered for use with patients in routine practice settings and in evaluative studies including clinical trials. Measurement responsiveness and minimal important change are currently being assessed. (J Rheumatol First Release August 1 2010; doi:10.3899/jrheum.091359)

Key Indexing Terms:

ANKYLOSING SPONDYLITIS QUALITY OF LIFE PATIENT-REPORTED OUTCOME

Ankylosing spondylitis (AS) is an incurable, inflammatory disease, primarily affecting the pelvis and spine¹. It can have a profound influence on health status and quality of life

From the RCN Research Institute, School of Health and Social Studies, University of Warwick, Coventry, UK; National Resource Centre for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Arthritis Research Campaign National Primary Care Centre, Keele University; and Staffordshire Rheumatology Centre, Haywood Hospital, Burslem, Stoke-on-Trent, Staffordshire, UK.

Supported by an unrestricted educational research grant from Wyeth UK.

K.L. Haywood, DPhil, RCN Research Institute, School of Health and Social Studies, University of Warwick, Arthritis Research Campaign National Primary Care Centre, Keele University; A.M. Garratt, PhD, National Resource Centre for Rehabilitation in Rheumatology, Diakonhjemmet Hospital; K.P. Jordan, PhD, Arthritis Research Campaign National Primary Care Centre, Keele University; E.L. Healey, PhD; J.C. Packham, MD, Arthritis Research Campaign National Primary Care Centre, Keele University, Staffordshire Rheumatology Centre, Haywood Hospital.

Address correspondence to Dr. K.L. Haywood, Royal College of Nursing Research Institute, School of Health and Social Studies, University of Warwick, Coventry, CV4 7AL, UK. E-mail: k.l.haywood@warwick.ac.uk
Accepted for publication May 11, 2010.

(QOL)². Consequently, appropriate assessment of disease influence and outcomes of healthcare raise complex issues. The AS Assessment group (ASAS) have defined 5 core assessment domains: functional ability, spinal mobility, pain, spinal stiffness, and global assessment^{3,4}. Although acknowledged as an important concept, QOL was not included due to uncertainty over measurement selection^{3,4}.

QOL comprises physical, social, and psychological issues alongside perceptions of health status, cognition, sexuality, spirituality, and personal productivity^{5,6,7}. Since the initial ASAS recommendation, 2 AS-specific measures of QOL have been published: the ASQoL questionnaire⁸, a standardized measure, and the Patient Generated Index-AS (PGI-AS)⁹, an individualized measure.

Comparable levels of reliability and construct validity have been reported for these measures^{9,10}. However, several areas frequently nominated by patients as important aspects of QOL were not included in the ASQoL, raising concerns over content validity⁹. Moreover the ASQoL's yes/no response scales may be poorly accepted¹⁰, prevent

detailed descriptions of health^{5,11}, and may have low levels of responsiveness to small, but important changes¹². The PGI-AS has good content validity, but the individualized format may limit the feasibility in clinical trials⁹.

The objective of our study was to develop and evaluate a new AS-specific measure of QOL based on the views of patients from a large UK-based survey.

MATERIALS AND METHODS

Development of a patient-reported outcome measure (PROM). A 4-stage strategy was adopted: item development, pretesting, pilot evaluation, and data collection (Figure 1). Different patient samples were employed at all stages (Table 1). All participants were diagnosed with AS¹³ and were aged over 18 years. Ethical approval was granted by North Staffordshire Local Research Ethics Committee.

Stage 1: Item development. Item development was based on the individual's subjective experience of the daily effects of AS^{9,14}. Items were elicited from patients through exploratory in-depth interviews⁹ and completion of the PGI-AS, where patients listed up to 5 of the most important areas of life affected by AS^{9,15}. A literature review identified existing questionnaires that might inform development¹².

Following content analysis of interview transcripts and completed PGI-AS questionnaires, verbatim statements reflecting important and common themes were listed¹⁶. Related themes were highlighted, grouped together, and organized by conceptual categories by 3 of the authors (KLH, AMG, JCP). Following assessment of completeness, ambiguity, and repetition¹⁷, 57 items were included in the initial measure. Some item pairs that were not conceptually distinct were included to explore the patient-preferred format during pretesting and data quality during data collection.

Stage 2: Pretesting – Cognitive debriefing. Consecutive patients attending the outpatient clinics at the Staffordshire Rheumatology Centre (SRC) were invited to participate in stage 2.

Cognitive debriefing interviews, including item rephrasing, verbal probing, and thinking aloud assessed if patients experienced difficulties with any part of the measure^{17,18,19,20}. Patients commented on structure, response format, and missing concepts. Patients self-completed a pre-selected subset of items and a series of open questions were posed, seeking comments in relation to question stem, response options, and timeframe. The results of 4 interviews were assessed and content revised to address specific problems raised, or key issues highlighted for further evaluation. This process was repeated until new concerns did not arise.

Four clinicians and 2 physiotherapists commented on the face validity and clinical relevance of the measure.

Stage 3: Pilot evaluation. The measure was posted to a random sample of 51 patients identified from the SRC database, to comment on content and structure. Data quality was assessed.

Stage 4: Data collection. The measure was then evaluated in a UK-based postal survey of 1000 patients with AS randomly selected from existing databases of 10 secondary care rheumatology centers²¹. A questionnaire included the Evaluation of Ankylosing Spondylitis Quality of Life (EASI-QoL), disease-specific measures¹², domain-specific, generic health measures²², and 2 health transition items.

The disease-specific measures included the Bath AS Disease Activity Index (BASDAI)²³, the Bath AS Functional Index (BASFI)²⁴, and the ASQoL⁸. The domain-specific Hospital Anxiety and Depression Scale (HADS) assesses emotional well-being²⁵.

Generic measures included the Medical Outcomes Study Short Form-36 (SF-36; version 2)²⁶ and the EuroQoL EQ-5D²⁷. The SF-36 provides a score for 8 domains of health: physical function (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), mental health (MH), and role-emotional (RE). The EuroQoL EQ-5D incorporates utilities or preferences for health states to generate an index score of QOL.

Nonresponders were sent reminders at 2 and 4 weeks. Respondents were sent a second questionnaire 2 weeks after receipt of the baseline questionnaire for purposes of assessing test-retest reliability.

Statistical analysis of Stage 4. Statistical analyses related to data collected in stage 4 and included consideration of data quality, dimensionality, Rasch analysis, and tests of external construct validity^{17,28,29,30,31,32}.

Data quality. Items with missing data over 10%, presence of end-effects (> 80%), excessive (> 40%) or minimal (< 10% aggregated adjacent response options) levels of endorsement, and item-item correlations > 0.70^{17,31,32} were considered for removal. Where 2 items were not considered conceptually distinct those with poorer data quality were considered for removal.

Confirmatory factor analysis. Four potential domain structures were hypothesized, informed by patient interviews⁹, AS core domains^{3,4}, and relevant literature^{2,5,9,33,34,35,36}: single domain; 2 domains (PF, QOL); 3 domains (PF, emotional well-being, social participation); and 4 domains (PF, disease activity, emotional well-being, social participation).

Assessment of the extent to which the data fitted these structures was performed using confirmatory factor analysis within the framework of structural equation modeling using maximum likelihood estimation and AMOS 7.0 software³⁷. Statistical significance of parameter estimates was evaluated. Goodness of fit was assessed using the comparative fit index (> 0.90 indicated good fit), the standardized root mean-square residual (< 0.08), root mean-square approximation (< 0.06–0.08), and Akaike's information criteria (smallest value indicating best fitting model)^{37,38}. Misfit of items to domains was examined using the modification indices of the error covariances, with large values indicating possible overlap between items, and the modification indices relating to the regression weights to ascertain possible misloading of items on a domain.

Rasch analysis. The extent to which the selected domains satisfied the Rasch measurement model was investigated using RUMM 2020 software³⁹. In the Rasch model, the probability of a specified response is determined based on the person's overall level of ability and the difficulty of the item. Items fitting poorly to this underlying model were considered for removal. Overall fit was assessed by examining item-person interaction statistics. The item-trait interaction chi-squared statistic was calculated; a significant result suggests the ordering of difficulty of items varies across the scale and hence poor fit. Individual item-fit statistics were calculated to see how well individual items fitted the model. Threshold disordering was examined to assess inconsistent or illogical use of response items. This may mean respondents have difficulty discriminating between item response options due to the number of options or because they have similar labels⁴⁰. Differential item functioning was investigated to test whether both sexes and both age groups (age ≤ 49, ≥ 50 yrs) responded similarly to each item⁴⁰.

Reliability. Internal consistency was assessed using item-total correlation and Cronbach's alpha¹⁷. Test-retest reliability was assessed for patients indicating no change in AS-specific health at 2 weeks¹⁷ by the intraclass correlation coefficient (2,1)⁴¹. For group comparisons, levels of reliability > 0.70 have been recommended, and for evaluation of individuals, levels > 0.90 are required¹⁷.

Validity. The validity of the EASI-QoL was assessed through comparisons with AS-specific, domain-specific, and generic measures. Hypothesized associations were considered a priori. The convergent validity of related dimensions was assessed by correlation.

It was hypothesized that the EASI-QoL disease activity (DA) domain would have a high level of correlation with the BASDAI (> 0.70); the physical function (PF) domain would have a high correlation with the BASFI (> 0.70); and the emotional well-being domain would have a high correlation with the HADS domain scores (> 0.70).

The 4 domains of the EASI-QoL would have moderate to high levels of correlation with the related domains of the SF-36 in the range 0.50 to 0.70: that is, EASI-QoL DA with SF-36 BP and VT; EASI-QoL PF with SF-36 PF and RP; EASI-QoL emotional well-being with SF-36 MH and RE; and EASI-QoL social participation (SP) with SF-36 SF and GH.




Figure 1. Development stages of the EASiQoL. *Responsiveness and minimal important change (MIC) to be reported in a followup publication.

Extreme groups validity. It was hypothesized that patients who reported bothersomeness (SF-36 item 8) or being unemployed or retired due to ill health would also report higher EASi-QoL domain scores, suggesting worse levels of health. Independent t-tests compared the mean domain scores between groups.

Acceptability. Consecutive patients attending the outpatient clinics at the SRC were invited to consider the final version of the EASi-QoL and commented on item relevance and acceptability during face to face interviews. SRC clinicians and physiotherapists with a specialist interest in AS also considered the measure.

Table 1. Patient characteristics for the 4 stages of EASi-QoL development.

Characteristic	Stage 1: Item Development		Stage 2: Pretesting	Stage 3: Pilot	Stage 4: Data Collection	
	Interviews, n = 29	Clinic Survey, n = 159	Postal Survey, n = 303	Interviews, n = 27	Postal Self-completion, n = 36	Postal Self-completion, n = 612
No. male (%)	24 (82.8)	132 (83.5)	221 (72.9)	22 (81.0)	29 (80.0)	434 (71.6)
Age, yrs						
Mean (SD)	48.41 (10.2)	48.70 (12.0)	46.10 (12.3)	54.0 (11.2)	55.30 (11.5)	50.8 (12.2)
Range	31–69	20–74	18–79	28–76	29–79	20–81
AS symptom duration, yrs						
Mean (SD)	—	20.90 (10.5)	20.04 (12.0)	—	—	22.4 (12.4)
Range	—	1–58	1–60	—	—	1–61
AS diagnosis duration, yrs						
Mean (SD)	11.0 (10.7)	15.5 (11.8)	14.1 (11.9)	19.0 (11.5)	18.0 (11.3)	17.3 (11.7)
Range	2–41	1–49	0–56	3–49	0.5–43	1–60

This multicenter cross-sectional survey was approved by the North Staffordshire Local Research Ethics Committee and the 10 center-specific NHS Trusts. Written consent was obtained from all patients according to the Declaration of Helsinki.

RESULTS

Stage 1: Item development. The literature review, patient interviews (n = 29), and completion of the PGI-AS (total n = 462)^{9,10,12} contributed to a 57-item measure (Figure 1) that addressed a range of QOL dimensions: cognitive function, emotional well-being, global well-being, personal constructs, physical function, role activities, social well-being, and symptoms⁵.

Following considerations of patient acceptability and score precision^{5,26}, a 5-point response scale was selected, scored from 0 to 4. Three response scales deemed most appropriate to the individual items were used: “not limited at all” to “totally limited/unable to do,” “none of the time” to “all of the time,” and “not at all” to “extremely.”

Stage 2: Pretesting. Twenty-seven patients were interviewed (Table 1). The measure was relevant to their experience of AS and included important issues. Fourteen items were removed to reduce repetition and minor modifications made. Respondents considered the response “applies to you today” to be preferable for items relating to physical functioning. For the remaining items a one-week recall period was preferred.

Stage 3: Pilot evaluation. Thirty-six (70.6%) patients responded to the pilot postal survey (Table 1). Thirty-two (89%) respondents completed all items; 4 completed 98% of items, with 4 different items being omitted. Respondents identified only minor problems; 1 item was removed and some wording changes were made. The revised 42-item measure retained the top 20 areas reported as important by AS patients⁹ and a wide range of QOL concerns.

Stage 4: Data collection. A total of 612 (64.0%) patients returned a completed postal questionnaire; 489 returned questionnaires at 2 weeks (80.2%) (Table 1).

Data quality. All 42 items were completed by 512 patients (84%). The mean number of missing responses was 3.7 (SD 9.2). The majority of items had 4 or fewer missing responses. The largest number of missing responses for one patient was 14. The item relating to the effect of AS on “intimate or sexual relationships” had the most missing data (9.8%).

On the 0–4 response scale, means ranged from 0.61 (sitting — 15 minutes) to 2.18 (pain or discomfort — duration). The item “drinking from a small can or glass” had the highest floor effect of 65.1% (“not limited”). The item “walking one mile” had the highest ceiling effect of 18.6% (“totally limited/unable to do”). Eight items were removed due to item duplication and poor data quality (Table 2).

Confirmatory factor analysis. The 4-domain structure of physical function, disease activity, emotional well-being, and social participation that included the remaining 34 items gave the best model fit, but below recommended levels. Items loaded onto the hypothesized domains; however, the modification indices between some items suggested overlap. Seven items were removed based on the modification indices, their relative strength of loading on a domain, and the earlier data quality assessment (Table 2).

Goodness of fit statistics for the remaining 27 items on 4 domains were satisfactory.

Rasch analysis of domains. Physical function. There was some initial item misfit, with one item (“sitting 2 hours”) showing poor fit, some differential item functioning on one item by sex and age (“bending down”), and threshold disordering for another item (“walking 1 mile”). Model fit was good after removal of the “sitting 2 hours” and “bending down” items, all individual items fitted the model well, and threshold ordering was satisfactory.

Disease activity. Assessment of model fit suggested a slight overall misfit but no specific individual item misfit. There was some slight uniform differential item functioning by sex for 2 items (“energy” and “stiffness”), but given the satisfactory fit all 4 items were retained.

Table 2. EASi-QoL domain structures: long-form, pre-confirmatory factor analysis (CFA), pre-Rasch, and final 20-item measure.

EASi-QoL	Long-form, 42 items	Pre-CFA, 34 items	Pre-Rasch, 27 items	Final, 20 items
Physical function				
Item 1 Lifting	X	X	X	X
Item 2 Walking - 1 mile	X	X	X	X
Item 3 Walking - 100 meters	X			
Item 4 Stairs	X	X		
Item 5 Standing - 30 minutes	X	X	X	X
Item 6 Standing - 5 minutes	X			
Item 7 Sitting - 2 hours	X	X	X	
Item 8 Sitting - 15 minutes	X			
Item 9 Lying down in bed	X	X		
Item 10 Changing position in bed	X	X		
Item 11 Getting up from sitting	X	X	X	X
Item 12 Find comfy position	X	X	X	X
Item 13 Drinking from a small glass or can	X			
Item 14 Bending down	X	X	X	
Item 15 Toilet	X	X		
Item 16 Washing	X	X		
Item 17 Dressing	X	X	X	X
Disease activity				
Item 28 Pain - severity	X	X	X	X
Item 29 Pain - duration	X			
Item 30 Sleep	X	X	X	X
Item 31 Energy	X	X	X	X
Item 34 Stiffness	X	X	X	X
Emotional well-being				
Item 22 Embarrassed or self-conscious—how often	X	X	X	X
Item 26 Control over AS	X	X	X	
Item 27 Worry about future	X	X	X	X
Item 32 Concentration	X	X	X	X
Item 33 Drive or motivation	X	X	X	X
Item 38 Frustration	X	X	X	
Item 39 Embarrassed or self-conscious—amount	X			
Item 40 Downhearted	X	X	X	X
Social participation				
Item 18 Interfere with work	X	X	X	X
Item 19 Hobbies and pastimes	X	X	X	
Item 20 Social activities	X	X		
Item 21 Family life	X	X	X	X
Item 23 Intimate or sexual relationships	X	X	X	
Item 24 Travel by car	X	X	X	X
Item 25 Slowing down	X	X	X	
Item 35 Doing errands	X			
Item 36 Jobs around the home	X			
Item 37 Physically active	X	X	X	X
Item 41 Medication	X	X		
Item 42 Quality of life	X	X	X	X

AS: ankylosing spondylitis.

Emotional well-being. Model fit was initially poor and there was a significant item-trait interaction. Removal of 2 items improved the model, although overall fit remained unsatisfactory with 2 further items (“embarrassed” and “downhearted”) exhibiting poor fit. The negative fit residual (−3.41) for “downhearted” suggested a high level of discrimination and hence possible redundancy of this item, in that patients not downhearted are scoring less than expected

and those very downhearted are scoring above expectation. The “embarrassed” item indicated low levels of discrimination. However, given the importance attributed to these items by patients it was decided to retain them.

Social participation. The model fit statistics suggested some misfit for 3 items. Removal of these items improved the model fit.

Confirmatory factor analysis was performed on the final 20 items and showed good fit.

The 20 items retained had low levels of missing data and acceptable evidence of end-effects, as shown in Table 3. Item-total correlations ranged between 0.66 and 0.84, and Cronbach's alpha ranged between 0.88 and 0.92 (Table 3).

Scoring the EASi-QoL. Scores are computed by summing items (each scored 0–4), where not more than one item per relevant domain is missing. Mean domain scores are imputed for missing items. Lower scores on the EASi-QoL indicate a better AS-related quality of life. The 20-item EASi-QoL is included below (Appendix).

Reliability. The intraclass correlation coefficients (2,1) for those patients indicating no change in their AS-specific health at 2 weeks were all above 0.90, except for disease activity (0.88), the recommended criterion for individual level assessment (Table 3).

Validity. As hypothesized, EASi-QoL domains had high correlations with AS-specific questionnaires measuring related constructs: the disease activity domain with the BASDAI and the PF domain with the BASFI, which were the highest correlations for these two EASi-QoL domains (Table 4).

As hypothesized, the strongest correlations between EASi-QoL and SF-36 were for the domains measuring related constructs: EASi-QoL PF with the SF-36 PF and RP domains; the EASi-QoL DA with the SF-36 BP and VT

domains; and EASi-QoL SP correlated strongly with the SF-36 SF and RP domains (Table 4). While high levels of correlation were found between the EASi-QoL emotional well-being and the SF-36 MH and RE domains, slightly higher correlations were found with the SF-36 SF, BP, and RP domains.

As hypothesized, the EASi-QoL emotional well-being domain had the strongest correlation with the HADS. Finally, the correlations with the EQ-5D were all in the range of 0.71–0.76, the largest being for social participation.

Extreme-groups validity. As hypothesized, compared with patients who were bothered by their ill health, those who were not bothered had significantly better levels of health on the EASi-QoL (all $p < 0.001$). Compared with those unable to work due to ill health, patients in work had significantly better levels of health on the EASi-QoL ($p < 0.001$; Table 5).

Acceptability. Seven patients self-completed the final EASi-QoL (71.4% were men; mean age 50 yrs, SD 14.2). All patients indicated that the measure was simple to complete and addressed areas of importance to their AS. Self-completion time approximated 5 minutes. The measure was felt to be clinically relevant by clinicians ($n = 4$) and physiotherapists ($n = 2$).

Table 3. EASi-QoL (20-item) item and scale properties at baseline ($n = 612$).

EASi-QoL*	Missing, %	Mean (SD)	Response Options		Item-Total Correlation (domain)	Cronbach alpha (ICC)
			Floor, %	Ceiling, %		
Domain 1: Physical function (0–24)	0.7	8.50 (5.96)	5.5	0.2	—	0.90 (0.93)
Item 1 (1) Lifting	0.5	1.80 (1.25)	16.6	10.8	0.78	—
Item 2 (2) Walking	0.5	1.52 (1.56)	41.5	18.6	0.80	—
Item 3 (5) Standing	0.7	1.63 (1.36)	27.1	11.5	0.79	—
Item 4 (11) Getting up from sitting	0.5	1.33 (1.02)	22.7	1.8	0.72	—
Item 5 (12) Find comfy position	0.5	1.47 (1.02)	17.2	2.1	0.71	—
Item 6 (17) Dressing	0.2	0.75 (0.91)	49.9	0.5	0.73	—
Domain 2: Disease activity (0–16)	0.2	7.86 (4.11)	1.6	4.6	—	0.88 (0.88)
Item 7 (28) Pain	0.2	2.02 (1.05)	4.3	8.3	0.81	—
Item 8 (30) Sleep	0.2	1.69 (1.29)	21.6	9.8	0.77	—
Item 9 (31) Energy	0.2	2.09 (1.25)	12.1	15.7	0.71	—
Item 10 (34) Stiffness	0.2	2.06 (1.18)	8.2	11.5	0.72	—
Domain 3: Emotional well-being (0–20)	0	6.27 (5.11)	12.2	0.7	—	0.91 (0.90)
Item 11 (22) Embarrassed	0.2	0.98 (1.19)	48.3	4.7	0.66	—
Item 12 (27) Worry about future	0.2	1.52 (1.29)	26.8	9.8	0.80	—
Item 13 (32) Concentration	0	1.05 (1.09)	40.2	1.0	0.76	—
Item 14 (33) Drive and motivation	0	1.48 (1.20)	26.6	4.7	0.82	—
Item 15 (40) Downhearted	0.2	1.23 (1.18)	35.0	4.7	0.84	—
Domain 4: Social participation (0–20)	0.2	7.15 (5.25)	8.9	0.7	—	0.92 (0.90)
Item 16 (18) Interfere with work	0.3	1.60 (1.21)	21.8	7.5	0.82	—
Item 17 (21) Family life	0.2	0.97 (1.15)	46.3	2.1	0.78	—
Item 18 (24) Travel by car	0.5	1.08 (1.15)	41.5	2.8	0.74	—
Item 19 (37) Keep physically active	0	1.70 (1.26)	19.9	8.8	0.82	—
Item 20 (42) Quality of life	0.2	1.82 (1.29)	17.3	13.3	0.82	—

* EASi-QoL scoring: Scores are computed by summing the items where no more than one item per relevant domain is missing. Domain mean scores are imputed for missing items. Items are scored 0–4. Lower scores indicate better health-related quality of life.

Table 4. Correlation between the EASi-QoL, AS-specific, domain-specific, and generic patient-reported outcome measures (Pearson correlation coefficient) (n = 612).

	EASi-QoL			
	Physical Function	Disease Activity	Emotional Well-being	Social Participation
AS-specific measures				
ASQoL	0.83	0.81	0.84	0.87
BASDAI	0.78	0.86	0.79	0.83
BASFI	0.87	0.73	0.71	0.83
Domain-specific				
HADS — anxiety	0.44	0.52	0.62	0.52
HADS — depression	0.60	0.62	0.72	0.69
HADS combined	0.56	0.60	0.71	0.64
Generic measures				
SF-36				
Physical functioning (PF)	-0.89	-0.67	-0.65	-0.77
Role physical (RP)	-0.78	-0.67	-0.70	-0.80
Body pain (BP)	-0.74	-0.79	-0.73	-0.80
Social functioning (SF)	-0.71	-0.67	-0.74	-0.80
Mental health (MH)	-0.49	-0.56	-0.69	-0.59
Role emotional (RE)	-0.64	-0.59	-0.68	-0.67
Vitality (VT)	-0.60	-0.69	-0.67	-0.68
General health (GH)	-0.65	-0.64	-0.68	-0.71
EuroQoL EQ-5D	-0.72	-0.72	-0.72	-0.76

Table 5. EASi-QoL scores according to patient reports of work status and bothersomeness (n = 612). Data are mean (SD).

EASi-QoL [†]	Work Status		Bothersomeness ^{††}	
	Employed, n = 319	Not Working, Ill Health, n = 159	Not Bothered, n = 262	Bothered, n = 348
Physical function (0–24)	5.4 (4.0)	14.4 (4.7)*	4.1 (3.4)	11.8 (5.2)*
Disease activity (0–16)	6.4 (3.6)	11.0 (3.4)*	4.8 (2.8)	10.2 (3.4)*
Emotional well-being (0–20)	4.3 (4.0)	10.3 (4.9)*	2.6 (2.7)	9.0 (4.8)*
Social participation (0–20)	4.8 (4.1)	12.0 (4.4)*	2.9 (2.5)	10.4 (4.5)*

[†] EASi-QoL scores: lower scores indicate better health-related quality of life. ^{††} Bothersomeness: assessed using question 8 of the SF-36: “How much did pain interfere with your normal work (including both work outside the home and housework)?” — responses “not at all” and “a little bit” defined as “not bothered”; additional responses defined as “bothered.” * All statistically significant at p < 0.01.

DISCUSSION

Well developed patient-reported outcome measures (PROM) provide a major source of evidence of the patient experience of disease impact and healthcare that can inform the decisions of patients, healthcare providers, and policy-makers. The challenge for quality of life assessment is to determine the uniqueness of disease impact to the individual^{9,14}. Development of the EASi-QoL was driven by evidence that factors reported as important by people with AS, including body image, mobility, and employment, were not adequately assessed by existing measures⁹. Moreover, in their initial recommendations, the ASAS group was unable to recommend QoL as a core assessment domain due to uncertainty over the best measurement approach^{3,4}.

Patients made a substantial contribution to the development of the EASi-QoL. Item content was informed by

patient interviews⁹, a UK-wide survey of AS patients^{9,15}, and piloting and followup interviews. The involvement of more than 550 patients during the development stages ensured that the lived experience of AS was assessed, which promoted the identification of important patient-derived themes. A subsequent large, UK-wide survey of AS patients provided the setting for evaluating essential measurement and practical properties. Responsiveness and minimal important change will be assessed in a followup of patients.

The low level of missing data for the 20-item EASi-QoL is evidence that the measure is acceptable to patients as a self-completed postal questionnaire. Moreover, self-completion takes approximately 5 minutes, which is acceptable for a measure that is to be used in routine practice, or alongside other PROM in clinical trials.

The 20 items contribute to a 4-domain measure of AS-

specific QOL: physical function, disease activity, emotional well-being, and social participation. The estimates for inter-rater consistency and test-retest reliability suggests that the EASi-QoL is suitable for applications involving groups of patients, for example, in clinical trials, and on an individual basis, for example, in a routine practice setting.

The results of comparisons with other PROM and AS-specific questions are evidence for the validity of the EASi-QoL. The high level of correlation with AS-specific measures, and the moderate to high correlations with the generic measures are evidence that the EASi-QoL is measuring the effects of AS across different aspects of health. Core sets have recently been described supporting classification of the influence of AS on functioning and health in accord with the World Health Organization's International Classification of Functioning and Health (WHO ICF)⁴². The ICF components include body structure, body function, activities and participation, and environmental factors. Future research will assess the relationship between the EASi-QoL domains and this framework. Further, the patients included in our study tended to have established disease; only 7% had symptoms for 5 years or less. The performance of the EASi-QoL in patients with short duration versus long-standing disease should be compared in a future study.

Growing evidence illustrates the significant everyday influence of AS across a range of physical, psychological, and social domains of health^{2,9,33,34,35}. However, pain, stiffness, and the physical effects of AS dominate AS core assessment^{3,4}. Less attention is directed to the emotional and social influence that reflects the broader concepts of QOL. Recently, the PROM Information System (PROMIS) initiative defined 5 constructs within a framework for measuring general health: pain, fatigue, emotional distress, physical function, and social role participation³⁶, all of which are identified within the EASi-QoL domains.

Although a single index score may simplify data analysis, reporting of the 4 domains is recommended as they measure distinct but related constructs. Combining distinct facets of health into an overall score could mask important differential effects of treatment on physical health, disease activity, emotional well-being, or social participation^{43,44}. Moreover, treatment choice and shared decision-making may be better informed by information provided across separate domains. However, index scores may more readily inform distinct treatment choices⁴⁴ and future research will assess the appropriateness of an index score.

There is considerably less guidance relating to the inclusion of patients' views about PROM content compared to those relating to quantitative psychometric criteria. Although there is general agreement that the most appropriate and valid PROM have involved patients in their development^{5,45}, this involvement is often cursory and poorly reported^{45,46}. Rarely do developers of PROM work collaboratively with patients as partners in the research process^{47,48}.

There is an important need for PROM development generally to more actively embrace patient involvement. The benefit from healthcare interventions may be masked unless their effectiveness is evaluated using outcomes that have relevance to patients and clinicians⁴⁶. The healthcare community needs to ensure appropriate patient involvement to help identify health domains and associated measures that reveal the experience of living with AS and response to treatment. Moreover, ASAS indicated their recommendations should be revised in light of new evidence for the assessment of QOL: the EASi-QoL, ASQoL, and PGI-AS all involved patients in their development and have evidence for reliability and construct validity. However, the broader content of the EASi-QoL, as reflected in its profile scores, makes it potentially more relevant to patients as a measure of QOL in AS. Concurrent evaluations of the EASi-QoL, ASQoL, and PGI-AS are recommended to further compare measurement and practical properties.

The EASi-QoL measures the influence of AS on QOL from the patient's perspective across 4 important QOL domains: physical function, disease activity, emotional well-being, and social participation. It is recommended as a new patient-derived measure of AS-specific quality of life that identifies issues of importance to patients.

ACKNOWLEDGMENT

The authors thank all the patients who participated in the study, and consultant rheumatologists, physiotherapists, and research nurses in the EASi-QoL study group — Dr. M. Bukhari (Royal Lancaster Infirmary), Dr. P. Creamer (Southmead Hospital), Prof. H. Gaston (Addenbrookes Hospital), Dr. L. Kay (Freeman Hospital), Dr. S. Linton (Nevill Hall Hospital), Dr. K. McKay (Torbay Hospital), Dr. D. Mulherin (Cannock Chase Hospital), Prof. R. Sturrock (Glasgow Royal Infirmary), and Dr. R. Withrington and Liz van Rossen (Kent and Canterbury Hospital).

REFERENCES

1. Russell AS. Ankylosing spondylitis – History. In: Klippel JH, Dieppe PA, editors. *Rheumatology*. 2nd ed. London: Mosby; 1998;1:14.1-2.
2. Ward MM. Quality of life in patients with ankylosing spondylitis. *Rheum Dis Clin N Am* 1998;24:815-27.
3. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. *J Rheumatol* 1997;24:2225-9.
4. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. *J Rheumatol* 1999;26:951-4.
5. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. *Health Technol Assess* 1998;2:i-iv, 1-74.
6. Naughton MJ, Shumaker SA. The case for domains of function in quality of life assessment. *Qual Life Res* 2003;12 Suppl 1:73-80.
7. Wolfe BJ, Sirois FM. Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease. *Qual Life Res* 2008;17:877-86.

APPENDIX

EASi-QoL
Evaluation of Ankylosing Spondylitis Quality of Life
A patient-reported outcome measure

Scoring

The EASi-QoL consists of 20 questions across the 4 domains of: physical function, disease activity, emotional wellbeing and social participation. Each question is scored 0-4. 0 indicates 'no limitation' increasing to 4 indicating 'extreme limitation'.

For example:

During the **past week**, how much did your Ankylosing Spondylitis interfere with your ability to keep physically active?

0 1 2 3 4
 Not at all A little bit Moderately Quite a bit Extremely

This question would be given a score of 1.

Missing data

If there is 1 missing answer in a domain, that question is scored as the mean of the questions answered in that domain, (add the completed scores in the domain, then divide by the number of questions answered).

If more than 1 question is missing in a domain, that domain cannot be scored.

Calculation of the domain scores and the total score

Domains		Possible score range
Domain 1: Physical function	Add scores of questions 1 to 6	0 - 24
Domain 2: Disease activity	Add scores of questions 7 to 10	0 - 16
Domain 3: Emotional well-being	Add scores of questions 11 to 15	0 - 20
Domain 4: Social participation	Add scores of questions 16 to 20	0 - 20

LIMITATIONS DUE TO YOUR ANKYLOSING SPONDYLITIS

The following questions ask about the problems that your Ankylosing Spondylitis has caused you. Please answer every question with a cross.
 If you are unsure about how to answer a question, please give the best answer you can.

These questions ask about activities you might do during a typical day.

Does your Ankylosing Spondylitis limit you in these activities today? If so, how much?

For each question, please cross the **one** response that **applies to you today**.

Please cross one box on each line

	Not limited at all	A little limited	Moderately limited	Very limited	Totally limited / unable to do
1. Lifting a child or heavy objects such as shopping or furniture	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Walking one mile	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Standing for 30 minutes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Getting up from a sitting position	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Finding a comfortable position in which you can relax	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Dressing or undressing yourself	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

We would now like to ask you questions about the **past week**. We understand that your Ankylosing Spondylitis may have changed from day to day but we would like you to give a response that shows how you have been **feeling on average over the past week**.

Please answer every question with a cross. If you are unsure about how to answer a question, please give the best answer you can.

7. During the **past week**, how much pain or discomfort did your Ankylosing Spondylitis cause you?
 None A little bit Moderately Quite a bit Extreme
8. During the **past week**, how much did your Ankylosing Spondylitis interfere with your sleep?
 Not at all A little bit Moderately Quite a bit Extremely
9. During the **past week**, how much of the time have you felt tired or lacking in energy because of your Ankylosing Spondylitis?
 None of the time A little of the time Some of the time Most of the time All of the time
10. During the **past week**, how much morning stiffness did your Ankylosing Spondylitis cause you?
 None at all A little bit Moderately Quite a bit Extreme
11. During the **past week**, how much of the time have you felt embarrassed or self-conscious because of your Ankylosing Spondylitis?
 None of the time A little of the time Some of the time Most of the time All of the time
12. During the **past week**, how much of the time has your Ankylosing Spondylitis caused you to worry about the future (including work, caring for others, your social life and staying active)?
 None of the time A little of the time Some of the time Most of the time All of the time
13. During the **past week**, how much did your Ankylosing Spondylitis interfere with your ability to concentrate (including reading, listening to someone talking or watching the television)?
 Not at all A little bit Moderately Quite a bit Extremely
14. During the **past week**, how much of the time have you lacked drive or motivation because of your Ankylosing Spondylitis?
 None of the time A little of the time Some of the time Most of the time All of the time
 Please answer every question with a cross. If you are unsure about how to answer a question, please give the best answer you can.
15. During the **past week**, how much of the time have you felt downhearted or low because of your Ankylosing Spondylitis?
 None of the time A little of the time Some of the time Most of the time All of the time
16. During the **past week**, how much of the time has your Ankylosing Spondylitis interfered with your normal work (including work both outside the home and housework)?
 None of the time A little of the time Some of the time Most of the time All of the time
17. During the **past week**, how much did your Ankylosing Spondylitis interfere with family life or friendships?
 Not at all A little bit Moderately Quite a bit Extremely
18. During the **past week**, how much did your Ankylosing Spondylitis interfere with traveling either by car or public transport (including buses or trains)?
 Not at all A little bit Moderately Quite a bit Extremely
19. During the **past week**, how much did your Ankylosing Spondylitis interfere with your ability to keep physically active?
 Not at all A little bit Moderately Quite a bit Extremely
20. During the **past week**, how much of the time did you feel that your Ankylosing Spondylitis was interfering with the quality of your life?
 None of the time A little of the time Some of the time Most of the time All of the time

8. Doward LC, Spoorenberg A, Cook SA, Dziedzic K, Dawes PT. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. *Ann Rheum Dis* 2003;62:20-6.
9. Haywood KL, Garratt AM, Dziedzic K, Dawes PT. Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the Patient Generated Index. *J Rheumatol* 2003;30:764-73.
10. Haywood KL, Garratt AM, Jordan K, Dziedzic K, Dawes PT. Disease-specific patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. *Rheumatology* 2002;41:1295-302.

11. McHorney CA, Cohen AS. Equating health status measures with item response theory: illustrations with functional status measures. *Med Care* 2000;38 Suppl:II43-II59.
12. Haywood KL, Garratt AM, Dawes PT. Patient-assessed health in ankylosing spondylitis: a structured review. *Rheumatology* 2005;44:577-86.
13. van der Linden SJ, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27:361-8.
14. Carr AJ, Higginson IJ. Are quality of life measures patient centred?

- BMJ 2001;322:1357-60.
15. Haywood KL. Health outcomes in ankylosing spondylitis: an evaluation of patient-based and anthropometric measures [DPhil thesis]. York: University of York; 2000.
 16. Bowling A. Measuring health. A review of quality of life measurement scales. Philadelphia: Open University Press, Buckingham; 1997.
 17. Streiner DL, Norman GR. Health measurement scales. A practical guide to their development and use. 3rd ed. Oxford: Oxford Medical Publications; 2003.
 18. Collins D. Pretesting survey instruments: an overview of cognitive methods. *Qual Life Res* 2003;12:229-38.
 19. Watt T, Rasmussen AK, Groenvold M, Bjorner JB, Watt SH, Bonnema SJ, et al. Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing. *Qual Life Res* 2008;17:1009-17.
 20. Christodoulou C, Jungaenel DU, DeWalt DA, Rothrock N, Stone AA. Cognitive interviewing in the evaluation of fatigue items: results from the patient-reported outcomes measurement information system (PROMIS). *Qual Life Res* 2008;17:1239-46.
 21. Healey EL, Haywood KL, Jordan KP, Garratt AM, Ryan S, Packham JC. Ankylosing spondylitis and its impact on sexual relationships. *Rheumatology* 2009;48:1378-81.
 22. Garratt AM, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. *BMJ* 2002;324:1417-9.
 23. Garrett S, Jenkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 1994;21:2286-91.
 24. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. *J Rheumatol* 1994;21:2281-5.
 25. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983;67:361-70.
 26. Ware JE, Kosinski M, Dewey JE. How to score Version Two of the SF-36 Health Survey. Lincoln, RI: QualityMetric Inc., 2000.
 27. EuroQoL Group. EuroQoL: a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199-208.
 28. Power M, Quinn K, Schmidt S; WHOQOL-OLD Group. Development of the WHOQOL-old module. *Qual Life Res* 2005;14:2197-214.
 29. Laidlaw K, Power MJ, Schmidt S; WHOQOL-OLD Group. The Attitudes to Ageing Questionnaire (AAQ): development and psychometric properties. *Int J Geriatr Psychiatry* 2007;22:367-79.
 30. Chachamovich E, Fleck MP, Trentini CM, Laidlaw K, Power MJ. Development and validation of the Brazilian version of the Attitudes to Aging Questionnaire (AAQ): An example of merging classical psychometric theory and the Rasch measurement model. *Health Qual Life Outcomes* 2008;6:5.
 31. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. *Health Technol Assess* 2004;8:iii, 1-48.
 32. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. McGraw-Hill Series in Psychology. New York: McGraw-Hill; 1994.
 33. Bostan EE, Borman P, Bodur H, Barça N. Functional disability and quality of life in patients with ankylosing spondylitis. *Rheumatol Int* 2003;23:121-6.
 34. Chorus AM, Miedema HS, Boonen A, van der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. *Ann Rheum Dis* 2003;62:1178-84.
 35. Dagfinrud H, Mengshoel AM, Hagen KB, Loge JH, Kvien TK. Health status of patients with ankylosing spondylitis: a comparison with the general population. *Ann Rheum Dis* 2004;63:1605-10.
 36. Castel LD, Williams KA, Bosworth HB, Eisen SV, Hahn EA, Irwin DE, et al. Content validity in the PROMIS social-health domain: a qualitative analysis of focus-group data. *Qual Life Res* 2008;17:737-49.
 37. Byrne BM. Structural equation modeling with AMOS: Basic concepts, applications and programming. Rahway, NJ: Lawrence Erlbaum Associates; 2001.
 38. Hu L-T, Bentler PM. Cut-off criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. *Structural Equation Modeling* 1999;6:1-55.
 39. Andrich D, Sheridan B, Luo G. RUMM 2020. Perth, Western Australia: RUMM Laboratory Pty Ltd.; 2007.
 40. Pallant JF, Tennant A. An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). *Br J Clin Psychol* 2007;46:1-18.
 41. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull* 1979;86:420-8.
 42. Boonen A, Braun J, van der Horst Bruinsma IE, Huang F, Maksymowych W, Kostanjsek N, et al. ASAS/WHO ICF Core Sets for ankylosing spondylitis: how to classify the impact of AS on functioning and health. *Ann Rheum Dis* 2010;69:102-7.
 43. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. *Brain* 2001;124:962-73.
 44. McDowell I. Measuring health: a guide to rating scales and questionnaires. 3rd ed. Oxford: Oxford University Press; 2006.
 45. Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. *Value Health* 2007;10 Suppl 2:S125-37.
 46. Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, et al. Patient-important outcomes in registered diabetes trials. *JAMA* 2008;299:2543-9.
 47. Hanley B, Bradburn J, Barnes M, Evans C, Goodare H, Kelson M, et al. Involving the public in NHS, public health and social care research: briefing notes for researchers. INVOLVE Support Unit. 2nd ed. Eastleigh, Hampshire, UK: INVOLVE; 2003.
 48. Staniszewska S, Jones N, Newburn M, Marshall S. User involvement in the development of a research bid: barriers, enablers and impacts. *Health Expect* 2007;10:173-83.